Morepen Laboratories Ltd
Morepen Laboratories Ltd Q2 FY26 Results & Presentation Highlights: Revenue, Margins & Order Book
Q2 FY26 investor presentation: what the company reported on revenue, margins and projects.
Based on Morepen Laboratories Ltd's Q2 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Pharma Business (Total Revenue): - Q2 FY26: Rs. EBITDA: - Q2'FY26 Consolidated: ₹41 Crores (up from ₹8 Crores in Q2'FY25 standalone) - Q2'FY26 Standalone: ₹33 Crores (up from ₹23 Crores in Q2'FY25 standalone) - Profit After Tax (PAT): - Q2'FY26 Consolidated: ₹35 Crores (up from ₹11 Crores in Q2'FY25 standalone) - Q2'FY26 Standalone: ₹14 Crores (up from ₹8 Crores in Q2'FY25 standalone) - Operating Margin: - Not explicitly stated as a percentage in the presentation, only absolute EBITDA and PAT figures reported.
From Morepen Laboratories Ltd's Q2 FY26 earnings-call transcript · updated 25 Sept 2026.
Revenue & Sales Performance
- Pharma Business (Total Revenue):
- Q2 FY26: Rs. 248 Crores
- Q2 FY25: Rs. 235 Crores
- YoY Growth: ~5.5%
- Pharma Business (Standalone Revenue):
- Q2 FY26: Rs. 374 Crores
- Q2 FY25: Rs. 395 Crores
- YoY Change: Slight decline (~5.3%)
- API Revenue:
- H1 FY26: Rs. 424 Crores
- H1 FY25: Rs. 455 Crores
- YoY Change: Decline (~6.8%)
- Medical Devices Revenue:
- Q2 FY26: Rs. 126 Crores
- Q2 FY25: Rs. 133 Crores
- YoY Change: Decline (~5.3%)
- Glucometer Sales:
- Q2 FY26 Revenue: Rs. 97 Crores (down from Rs. 103 Crores in Q2 FY25)
- Operating Profit (EBITDA):
- Consolidated Q2 FY26: Rs. 35 Crores (up from Rs. 29 Crores in Q1 FY26)
2 more points management made on revenue & sales performance
Profitability & Margins
See what Morepen Laboratories Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Morepen Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Morepen Laboratories Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹485 Cr, net profit ₹16 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Morepen Laboratories Ltd's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q1 FY26 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q4 FY22 earnings call →
- Q3 FY22 earnings call →
- Q2 FY22 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Jubilant Pharmova Ltd (Q2 FY26)
Q2’FY26 revenue grew by 12% YoY to Rs. Key investor presentation takeaways from Jubilant Pharmova Ltd's Q2 FY26 investor presentation — and how it ranks against
- Anuh Pharma Ltd (Q2 FY26)
185.88 Cr, a -0.32% change quarter-on-quarter; 6 months ended 30/09/2025: Rs. Key investor presentation takeaways from Anuh Pharma Ltd's Q2 FY26 investor presen
- Themis Medicare Ltd (Q2 FY26)
Q2 FY26 Net Revenue: ₹77.99 Cr, down 33.3% YoY from ₹117.01 Cr in Q2 FY25 (Page 8) . Key investor presentation takeaways from Themis Medicare Ltd's Q2 FY26 inve
- Lincoln Pharmaceuticals Ltd (Q2 FY26)
EBITDA: ₹2,927 Crore, a YoY increase of 10.4% . Key investor presentation takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY26 investor presentation — and how i
Frequently Asked Questions
What were Morepen Laboratories Ltd Q2 FY26 results?
Pharma Business (Total Revenue): - Q2 FY26: Rs. EBITDA: - Q2'FY26 Consolidated: ₹41 Crores (up from ₹8 Crores in Q2'FY25 standalone) - Q2'FY26 Standalone: ₹33 Crores (up from ₹23 Crores in Q2'FY25 standalone) - Profit After Tax (PAT): - Q2'FY26 Consolidated: ₹35 Crores (up from ₹11 Crores in Q2'FY25 standalone) - Q2'FY26 Standalone: ₹14 Crores (up from ₹8 Crores in Q2'FY25 standalone) - Operating Margin: - Not explicitly stated as a percentage in the presentation, only absolute EBITDA and PAT figures reported.
What is Morepen Laboratories Ltd share price analysis?
Morepen Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 56.4 with a market cap of ₹6,625 Cr. Investors should review the full earnings analysis for detailed insights.
Is Morepen Laboratories Ltd planning capital expenditure?
The provided investor presentation for Q2 FY26 does not explicitly mention any details regarding capex, capacity expansion, new plants, or projects including amounts, status, or timelines.
Keep Morepen Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.